REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedReview

Rosacea: Pathogenesis and Therapeutic Correlates.

Geng Ryan S Q, Bourkas Adrienn N, Mufti Asfandyar, Sibbald R Gary
Journal of cutaneous medicine and surgery2024DOI: 10.1177/12034754241229365
cathelicidinsinflammasome complexes

Quality Score

7/10

Citations

0

Subjects

Non-Human

Peptide Contacts Analysis

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of cathelicidins, inflammasome complexes in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Strong methodology makes this a valuable addition to the cathelicidins, inflammasome complexes evidence base. The findings here should inform future clinical trial design.

Key Findings

The review highlights the multifactorial nature of rosacea pathogenesis, emphasizing the role of pro-inflammatory pathways involving cathelicidins and inflammasome complexes. It also discusses how current treatments may target these pathways to manage symptoms.

Limitations

As a review paper, it does not present new experimental data but synthesizes existing knowledge, which might be limited by the availability and quality of previous studies.

How to Interpret This Research

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts Analysis

An article focusing on the latest review of rosacea pathogenesis and its implications for peptide therapy could attract interest from dermatologists and researchers interested in inflammatory skin conditions.

cathelicidinsinflammasome complexes

Unraveling Rosacea: Insights into Pathogenesis and Therapeutic Targets

Published: May 16, 2026 | Source: Journal of cutaneous medicine and surgery (2024) | Category: cathelicidins, inflammasome complexes

Overview

A recent review in the Journal of Cutaneous Medicine and Surgery provides a comprehensive analysis of rosacea's complex pathogenesis, highlighting the pivotal role of pro-inflammatory pathways involving cathelicidins and inflammasome complexes. This understanding could pave the way for more effective peptide-based therapies aimed at managing this chronic inflammatory condition.

Study Background

Rosacea is a common skin disorder characterized by persistent redness, visible blood vessels, bumps, and pimples primarily affecting the central face. Despite its prevalence, the exact cause of rosacea remains elusive, making it challenging to develop targeted treatments. Prior research has suggested that genetic predisposition, environmental factors, and immune system dysregulation are likely contributors to the development and progression of rosacea. However, a detailed understanding of the molecular mechanisms underlying these processes was lacking until now.

What the Research Found

The review by Geng et al. synthesizes existing knowledge on the pathogenesis of rosacea, emphasizing the critical role of pro-inflammatory pathways involving cathelicidins and inflammasome complexes. Cathelicidins are antimicrobial peptides that play a significant role in innate immunity; however, their dysregulation can lead to inflammation. Inflammasomes are multiprotein complexes that activate caspase-1, leading to the maturation of pro-inflammatory cytokines such as interleukin (IL)-1β and IL-18. The review highlights how these pathways interact with environmental triggers like UV radiation, heat, and certain foods, contributing to the varied clinical presentations of rosacea.

What This Means for Peptide Users

Understanding the role of cathelicidins and inflammasome complexes in rosacea pathogenesis could lead to more targeted peptide therapies. For instance, peptides that inhibit the activation of these pathways or modulate their activity might offer new avenues for treating symptoms effectively. While current treatments such as topical metronidazole and oral antibiotics have shown efficacy, they often come with side effects and do not address the underlying inflammatory mechanisms comprehensively.

Limitations and Caveats

As a review paper, this study does not present original experimental data but rather synthesizes existing literature. Therefore, its conclusions are limited by the availability and quality of previous studies. Additionally, while the proposed pathways provide a promising framework for understanding rosacea, further research is needed to validate these mechanisms in clinical settings.

How This Compares to Previous Research

Previous studies have also pointed towards an inflammatory basis for rosacea but lacked the detailed molecular insights provided by this review. The emphasis on cathelicidins and inflammasome complexes offers a more refined understanding of the disease's pathogenesis, aligning with recent advances in immunology and dermatology.

Our Analysis

PeptideVault views this review as an important step towards a deeper understanding of rosacea's underlying mechanisms. While it does not provide definitive answers, it sets the stage for future research that could lead to more effective therapeutic interventions. The identification of cathelicidins and inflammasome complexes as key players in rosacea pathogenesis opens up new possibilities for peptide-based therapies.

Key Takeaways

  • Pathogenesis Insights: Rosacea's development is linked to dysregulated pro-inflammatory pathways involving cathelicidins and inflammasome complexes.
  • Therapeutic Targets: Future treatments may focus on modulating these pathways, potentially offering more targeted relief from symptoms.
  • Further Research Needed: While promising, the proposed mechanisms require validation through clinical trials.

Original Source

Citation: Geng Ryan S Q, Bourkas Adrienn N, Mufti Asfandyar et al. (2024). Rosacea: Pathogenesis and Therapeutic Correlates.. Journal of cutaneous medicine and surgery. DOI: 10.1177/12034754241229365

Access: https://pubmed.ncbi.nlm.nih.gov/38450615/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the Peptide Contacts research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on cathelicidins, explore our research guides.

Citation

Geng Ryan S Q, Bourkas Adrienn N, Mufti Asfandyar et al.. (2024). Rosacea: Pathogenesis and Therapeutic Correlates.. Journal of cutaneous medicine and surgery. https://doi.org/10.1177/12034754241229365

View full text on PubMed

Related Papers

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Mendias Christopher L et al.· Sports medicine (Auckland, N.Z.)· 2026Review

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

Yuan Claire et al.· International journal of molecular sciences· 2026Review

Carbonless amino acids and a carbonless GHK peptide.

Skurski Piotr et al.· Physical chemistry chemical physics : PCCP· 2026Review

The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.

Wen Huijun et al.· Biogerontology· 2026Review

Glycyl-L-histidyl-L-lysine-Cu2

Hu Jing et al.· European journal of pharmacology· 2026Review

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Mayfield Cory K et al.· The American journal of sports medicine· 2026Review

Explore Further

Research Library

Browse all indexed papers

Research Guides

Plain-language peptide guides

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.